Cargando…

A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients

Efficacy of PA21 (sucroferric oxyhydroxide), a novel calcium-free polynuclear iron(III)-oxyhydroxide phosphate binder, was compared with that of sevelamer carbonate in an open-label, randomized, active-controlled phase III study. Seven hundred and seven hemo- and peritoneal dialysis patients with hy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Floege, Jürgen, Covic, Adrian C, Ketteler, Markus, Rastogi, Anjay, Chong, Edward M F, Gaillard, Sylvain, Lisk, Laura J, Sprague, Stuart M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4150998/ https://www.ncbi.nlm.nih.gov/pubmed/24646861 http://dx.doi.org/10.1038/ki.2014.58

Ejemplares similares

Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients
por: Floege, Jürgen, et al.
Publicado: (2015)

Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide
por: Covic, Adrian C., et al.
Publicado: (2017)

Iron kinetics following treatment with sucroferric oxyhydroxide or ferric citrate in healthy rats and models of anaemia, iron overload or inflammation
por: Floege, Jürgen, et al.
Publicado: (2020)

Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease–mineral bone disorder parameters in dialysis patients
por: Ketteler, Markus, et al.
Publicado: (2019)

Managing Phosphate Burden in Patients Receiving Dialysis: Beyond Phosphate Binders and Diet
por: Kalantar-Zadeh, Kamyar, et al.
Publicado: (2023)

Hyperphosphatemia in patients with ESRD: assessing the current evidence linking outcomes with treatment adherence
por: Covic, Adrian, et al.
Publicado: (2013)

Effects of iron-based phosphate binders on mortality and cardiovascular events in patients receiving maintenance dialysis
por: Tanaka, Akihito, et al.
Publicado: (2023)

Do we need new phosphate binders in dialysis?
por: Cozzolino, Mario, et al.
Publicado: (2020)

Phosphate binders in dialysis: better satisfied than sorry
por: Cozzolino, Mario, et al.
Publicado: (2021)

Iron-based phosphate binders: do they offer advantages over currently available phosphate binders?
por: Negri, Armando Luis, et al.
Publicado: (2015)

Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability
por: de Francisco, Angel L.M., et al.
Publicado: (2010)

High Phosphate-Binding Capacity of Oxylanthanum Carbonate with a Low Medication Volume: Comparison with Commercially Available Phosphate Binders
por: Sprague, Stuart M., et al.
Publicado: (2023)

Interventional study to improve adherence to phosphate binder treatment in dialysis patients
por: Hjemås, Bodil Jahren, et al.
Publicado: (2019)

Ferric Citrate, an Iron-Based Phosphate Binder, Reduces Health Care Costs in Patients on Dialysis Based on Randomized Clinical Trial Data
por: Rodby, Roger A., et al.
Publicado: (2015)

Phosphate binders for the treatment of chronic kidney disease: role of iron oxyhydroxide
por: Cernaro, Valeria, et al.
Publicado: (2016)

Management of hyperphosphataemia in chronic kidney disease—challenges and solutions
por: Ketteler, Markus, et al.
Publicado: (2013)

Intact FGF23 predicts serum phosphate improvement after combined nicotinamide and phosphate binder treatment in hemodialysis patients
por: Egli-Spichtig, Daniela, et al.
Publicado: (2023)

Phosphate binders as a cause of hypothyroidism in dialysis patients: practical indications from a review of the literature
por: Cataldo, Emanuela, et al.
Publicado: (2018)

Effect of the phosphate binder sucroferric oxyhydroxide in dialysis patients on endogenous calciprotein particles, inflammation, and vascular cells
por: Thiem, Ursula, et al.
Publicado: (2022)

Tolerability and efficacy of the intestinal phosphate binder Lantharenol(® )in cats
por: Schmidt, Bernard H, et al.
Publicado: (2012)

Survival with low- and high-flux dialysis
por: Sánchez-Álvarez, Emilio, et al.
Publicado: (2020)

Pharmacology of the Phosphate Binder, Lanthanum Carbonate
por: Damment, Stephen JP
Publicado: (2011)

The Infant KIdney Dialysis and Utrafiltration (I-KID) Study: A Stepped-Wedge Cluster-Randomized Study in Infants, Comparing Peritoneal Dialysis, Continuous Venovenous Hemofiltration, and Newcastle Infant Dialysis Ultrafiltration System, a Novel Infant Hemodialysis Device
por: Lambert, Heather, et al.
Publicado: (2023)

Meal phosphate variability does not support fixed dose phosphate binder schedules for patients treated with peritoneal dialysis: a prospective cohort study
por: Leung, Simon, et al.
Publicado: (2015)

Clustering phosphate and iron-related markers and prognosis in dialysis patients
por: Morooka, Hikaru, et al.
Publicado: (2021)

Differential effects of phosphate binders on pre-dialysis serum bicarbonate in end-stage kidney disease patients on maintenance haemodialysis
por: Thet, Zaw, et al.
Publicado: (2013)

Cost-effectiveness of phosphate binders among patients with chronic kidney disease not yet on dialysis: a long way to go
por: Rizk, Rana
Publicado: (2016)

European hemodialysis patient satisfaction with phosphate binders is associated with serum phosphorus levels: the Dialysis Outcomes and Practice Patterns Study
por: McCullough, Keith, et al.
Publicado: (2021)

Effectiveness and cost-efficiency of phosphate binders in hemodialysis
por: Fröschl, Barbara, et al.
Publicado: (2009)

Phosphate Metabolism in CKD Stages 3–5: Dietary and Pharmacological Control
por: Ketteler, Markus
Publicado: (2011)

Preparation of acid aluminum phosphate solutions for metakaolin phosphate geopolymer binder
por: Yankwa Djobo, Jean Noël, et al.
Publicado: (2021)

Rationale and design of Ferinject(®) Assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia
por: Anker, Stefan D., et al.
Publicado: (2009)

Efficacy and safety of disodium ascorbyl phytostanol phosphates in men with moderate dyslipidemia
por: Vissers, Maud N., et al.
Publicado: (2008)

Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism
por: Behets, Geert J, et al.
Publicado: (2015)

Impact of phosphate binders on quality of life in dialysis patients: Results from the prospective Dutch nOcturnal and hoME dialysis Study To Improve Clinical Outcomes study
por: Colombijn, Julia M. T., et al.
Publicado: (2022)

Effectiveness of iron polymaltose complex in treatment and prevention of iron deficiency anemia in children: a systematic review and meta-analysis
por: Mohd Rosli, Ritzzaleena Rosli, et al.
Publicado: (2021)

Effect of Phosphate Binders and a Dietary Iron Supplement on the Pharmacokinetics of a Single Dose of Vadadustat in Healthy Adults
por: Paulson, Susan K., et al.
Publicado: (2022)

Analysis of serum phosphate control and phosphate binder utilization in incident hemodialysis patients
por: Farrand, Kimberly F, et al.
Publicado: (2014)

Treatment of secondary hyperparathyroidism in non-dialysis CKD: an appraisal 2022s
por: Ketteler, Markus, et al.
Publicado: (2022)

Treatment of phosphate retention: The earlier the better?
por: Biggar, Patrick, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_fe0de1733vkdq4u3b7q58r4qph